Literature DB >> 12477718

Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure.

Satoshi Jodo1, John T Kung, Sheng Xiao, Derek V Chan, Seiichi Kobayashi, Masatoshi Tateno, Robert Lafyatis, Shyr-Te Ju.   

Abstract

The Jo2 anti-mouse CD95 monoclonal antibody induces lethality in mice characterized by hepatocyte death and liver hemorrhage. Mice bearing a defect in Fas expression or in the Fas-mediated apoptotic pathway are resistant to Jo2. Here we show that FcgammaRII knockout mice or mice with monoclonal antibody-blocked FcgammaRII are also resistant to Jo2. The critical FcgammaRII(+) cells are radioresistant and could not be reconstituted with splenic cells. Death of sinusoidal lining cells and destruction of sinusoids were observed, consistent with the characteristic liver hemorrhage and the selective FcgammaRII expression in sinusoidal lining cells but not hepatocytes. Hemorrhage developed coincident with hepatocyte death and the sharp rise of serum alanine aminotransferase and alanine aminotransferase. Invariably, moribund mice showed severe liver hemorrhage and destruction of sinusoids. The data demonstrate a novel mechanism by which the destruction of liver sinusoids, induced by the Jo2-mediated co-engagement of Fas and FcgammaRII, leads to severe hemorrhage and lethal fulminant hepatitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477718     DOI: 10.1074/jbc.M211229200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Agonistic antibodies to Fas induce a breach in the endothelial lining of the liver and a breakdown in B cell tolerance.

Authors:  M M Newkirk; U Nowak; E Skamene; D Iera; J Desbarats
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Johnny E Croy; Linda Schirtzinger; Stacy Torgerson; Matthew Breyer; Victor J Wroblewski
Journal:  MAbs       Date:  2016-07       Impact factor: 5.857

3.  Anti-apoptotic function of gelsolin in fas antibody-induced liver failure in vivo.

Authors:  Ludger Leifeld; Klaus Fink; Grazyna Debska; Magdalene Fielenbach; Volker Schmitz; Tilman Sauerbruch; Ulrich Spengler
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

4.  Protective effects of HFE7A, mouse anti-human/mouse Fas monoclonal antibody against acute and lethal hepatic injury induced by Jo2.

Authors:  Hiroko Yoshida; Kenji Watanabe; Shu Takahashi; Kimihisa Ichikawa
Journal:  Cytotechnology       Date:  2009-12-19       Impact factor: 2.058

5.  The TRAIL to arthritis.

Authors:  George C Tsokos; Maria Tsokos
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 6.  Principles of antibody-mediated TNF receptor activation.

Authors:  H Wajant
Journal:  Cell Death Differ       Date:  2015-08-21       Impact factor: 15.828

Review 7.  The Janus Face of Death Receptor Signaling during Tumor Immunoediting.

Authors:  Eimear O' Reilly; Andrea Tirincsi; Susan E Logue; Eva Szegezdi
Journal:  Front Immunol       Date:  2016-10-31       Impact factor: 7.561

8.  Disruption of the FasL/Fas axis protects against inflammation-derived tumorigenesis in chronic liver disease.

Authors:  Francisco Javier Cubero; Marius Maximilian Woitok; Miguel E Zoubek; Alain de Bruin; Maximilian Hatting; Christian Trautwein
Journal:  Cell Death Dis       Date:  2019-02-08       Impact factor: 8.469

9.  A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer.

Authors:  Derek V Chan; Rahul Sharma; Chiao-Ying A Ju; Steve R Roffler; Shyr-Te Ju
Journal:  J Biomed Sci       Date:  2013-03-05       Impact factor: 8.410

10.  CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

Authors:  Johannes Nelke; Juliane Medler; Daniela Weisenberger; Andreas Beilhack; Harald Wajant
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.